15 September 2016
Participation in a major Horizon 2020 project
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been invited to participate as an industrial collaborator for an upcoming Horizon 2020 (H2020) project. The wholly grant-funded project addresses a pressing clinical need using cell-based tissue regeneration techniques. Collagen Solutions is already a consortium partner on an existing H2020 program to develop formulations of collagen for the delivery of therapeutic moieties for the treatment of Parkinson's Disease.
The project is expected to begin in early 2017 and will run for approximately five years, over which Collagen Solutions will receive approximately €500,000 of European Union (EU) funding, and is subject to a formalised Grant Agreement between the consortium members and the European Commission.
Jamal Rushdy, CEO of Collagen Solutions commented: "Our selection as an industrial collaborator in a second H2020 project recognises the leadership position of Collagen Solutions in researching, developing and providing unique collagen based biomaterials used in advanced regenerative medicine therapies. Our participation further enhances our scientific expertise in these areas, which also provides greater value to the development partners we serve."
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.
About Horizon 2020:
Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over seven years (2014 to 2020). Collagen Solutions has been advised that it will be awarded the grant under the Health section of Horizon 2020 and full details will be made available in the near future. The Health Programme is designed to find solutions to the many chronic and infectious diseases, as well as the inevitable effects of a deterioration of health in an ageing population that will need to be addressed as the number of people in the EU aged over 65 will have grown by over 70% in 2050.
|Collagen Solutions Plc|
|Jamal Rushdy, CEO||Contact via Walbrook|
|Panmure Gordon & Co (Nominated Adviser and Broker)|
|Freddy Crossley, Duncan Monteith (Corporate Finance)||Tel: 020 7886 2500|
|Maisie Atkinson (Corporate Sales)||Tel: 020 7886 2905|
|Walbrook PR Ltd||Tel: 020 7933 8780 or email@example.com|
|Mike Wort||Mob: 07900 608 002|
|Anna Dunphy||Mob: 07876 741 001|